Axsome Therapeutics, Inc. (AXSM): Cash & Equivalents
$322.93M
As of 2025-12-31
$319.85M
As of 2026-06-30
+17.2%
3-year compound annual growth
+11.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $322.93M | +2.4% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $315.35M | -18.3% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $386.19M | +92.3% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $200.84M | +132.3% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $86.47M | -53.0% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $183.88M | -16.4% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $219.97M | n/a | 2021-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $79.15M | -56.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
| Insmed Inc (INSM) | 2025-12-31 | $510.44M | -8.0% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗